Antibody-drug conjugates (ADCs) are increasingly powerful medicines for targeted cancer therapy. Inspired by the trend to further improve their therapeutic index by generation of homogenous ADCs, we report here how the clinical-stage GlycoConnect™ technology uses the globally conserved
N
-glycosylation site to generate stable and site-specific ADCs based on enzymatic remodeling and metal-free click chemistry. We demonstrate how an engineered endoglycosidase and a native glycosyl transferase enable highly efficient, one-pot glycan remodeling, incorporating a novel sugar substrate 6-azidoGalNAc. Metal-free click attachment of an array of cytotoxic payloads was highly optimized, in particular by inclusion of anionic surfactants. The therapeutic potential of GlycoConnect™, in combination with HydraSpace™ polar spacer technology, was compared to that of Kadcyla® (ado-trastuzumab emtansine), showing significantly improved efficacy and tolerability.
After several notable clinical failures in early generations, antibody–drug conjugates (ADC) have made significant gains with seven new FDA approvals within the last 3 years. These successes have been driven by a shift towards mechanistically informed ADC design, where the payload, linker, drug-to-antibody ratio, and conjugation are increasingly tailored to a specific target and clinical indication. However, fundamental aspects needed for design, such as payload distribution, remain incompletely understood. Payloads are often classified as “bystander” or “nonbystander” depending on their ability to diffuse out of targeted cells into adjacent cells that may be antigen-negative or more distant from tumor vessels, helping to overcome heterogeneous distribution. Seven of the 11 FDA-approved ADCs employ these bystander payloads, but the depth of penetration and cytotoxic effects as a function of physicochemical properties and mechanism of action have not been fully characterized. Here, we utilized tumor spheroids and pharmacodynamic marker staining to quantify tissue penetration of the three major classes of agents: microtubule inhibitors, DNA-damaging agents, and topoisomerase inhibitors. PAMPA data and coculture assays were performed to compare with the 3D tissue culture data. The results demonstrate a spectrum in bystander potential and tissue penetration depending on the physicochemical properties and potency of the payload. Generally, directly targeted cells show a greater response even with bystander payloads, consistent with the benefit of deeper ADC tissue penetration. These results are compared with computational simulations to help scale the data from in vitro and preclinical animal models to the clinic.
GlycoConnect
technology can be readily adapted to provide different
drug-to-antibody ratios (DARs) and is currently also evaluated in
various clinical programs, including ADCT-601 (DAR2), MRG004a (DAR4),
and XMT-1660 (DAR6). While antibody-drug conjugates (ADCs) typically
feature a DAR2–8, it has become clear that ADCs with ultrapotent
payloads (e.g., PBD dimers and calicheamicin) can only be administered
to patients at low doses (<0.5 mg/kg), which may compromise effective
biodistribution and may be insufficient to reach target receptor saturation
in the tumor. Here, we show that GlycoConnect technology can be readily
extended to DAR1 ADCs without the need of antibody re-engineering.
We demonstrate that various ultrapotent, cytotoxic payloads are amenable
to this methodology. In a follow-up experiment, HCC-1954 tumor spheroids
were treated with either an AlexaFluor647-labeled DAR1 or DAR2 PBD-based
ADC to study the effect on tumor penetration. Significant improvement
of tumor spheroid penetration was observed for the DAR1 ADC compared
to the DAR2 ADC at an equal payload dose, underlining the potential
of a lower DAR for ADCs bearing ultrapotent payloads.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.